Your browser is no longer supported. Please, upgrade your browser.
Settings
LIFE [NASD]
aTyr Pharma, Inc.
Index- P/E- EPS (ttm)-2.34 Insider Own0.30% Shs Outstand14.10M Perf Week1.28%
Market Cap76.78M Forward P/E- EPS next Y-1.79 Insider Trans116.41% Shs Float13.32M Perf Month29.35%
Income-25.10M PEG- EPS next Q-0.51 Inst Own45.80% Short Float5.27% Perf Quarter-22.48%
Sales2.40M P/S31.99 EPS this Y74.80% Inst Trans21.92% Short Ratio0.79 Perf Half Y2.59%
Book/sh3.52 P/B1.35 EPS next Y6.80% ROA-54.90% Target Price- Perf Year27.27%
Cash/sh3.14 P/C1.51 EPS next 5Y13.00% ROE-67.20% 52W Range2.93 - 8.33 Perf YTD22.68%
Dividend- P/FCF- EPS past 5Y42.60% ROI- 52W High-42.86% Beta2.03
Dividend %- Quick Ratio11.70 Sales past 5Y- Gross Margin- 52W Low62.46% ATR0.25
Employees43 Current Ratio11.70 Sales Q/Q1325.70% Oper. Margin- RSI (14)63.53 Volatility4.67% 5.93%
OptionableYes Debt/Eq0.00 EPS Q/Q-299.10% Profit Margin- Rel Volume0.28 Prev Close4.73
ShortableYes LT Debt/Eq0.00 EarningsMay 13 AMC Payout- Avg Volume888.28K Price4.76
Recom1.80 SMA207.30% SMA5014.53% SMA20015.31% Volume258,822 Change0.63%
May-10-21Initiated Laidlaw Buy $18
Aug-17-20Upgrade H.C. Wainwright Neutral → Buy $13
Mar-04-20Initiated ROTH Capital Buy $15
Mar-02-20Initiated Oppenheimer Outperform $8
Feb-14-18Downgrade JP Morgan Neutral → Underweight
Sep-07-17Initiated Piper Jaffray Overweight $7
Dec-13-16Downgrade JP Morgan Overweight → Neutral
Dec-16-15Initiated Citigroup Neutral
Jun-01-15Initiated JP Morgan Overweight $44
Jun-01-15Initiated Citigroup Buy $32
Jun-10-21 04:30PM  
Jun-09-21 12:05PM  
Jun-02-21 04:58AM  
May-28-21 12:20PM  
May-25-21 08:00AM  
May-19-21 08:00AM  
May-13-21 05:20PM  
04:05PM  
03:15PM  
May-12-21 08:00AM  
May-11-21 08:00AM  
May-06-21 08:00AM  
May-04-21 03:00PM  
Apr-20-21 08:00AM  
Apr-14-21 09:42AM  
08:00AM  
Apr-09-21 08:00AM  
Apr-08-21 08:00AM  
Mar-27-21 04:27AM  
Mar-24-21 08:16AM  
Mar-23-21 04:46PM  
04:05PM  
03:15PM  
Mar-19-21 08:00AM  
Mar-17-21 02:13AM  
Mar-16-21 08:00AM  
Mar-15-21 08:00AM  
Mar-11-21 11:45AM  
08:00AM  
Mar-10-21 08:00AM  
Feb-25-21 08:00AM  
Feb-12-21 01:55PM  
Feb-11-21 08:00AM  
Feb-09-21 08:00AM  
02:55AM  
Feb-04-21 11:53AM  
Jan-25-21 08:00AM  
Jan-22-21 08:00AM  
Jan-14-21 08:00AM  
Jan-07-21 07:00AM  
Jan-04-21 04:15PM  
Dec-21-20 07:00AM  
Dec-02-20 10:48PM  
Nov-12-20 04:05PM  
03:15PM  
Nov-11-20 07:00AM  
Nov-10-20 07:00AM  
Nov-05-20 12:30PM  
07:00AM  
Oct-29-20 07:00AM  
Oct-27-20 07:00AM  
Oct-26-20 07:00AM  
Oct-07-20 08:00AM  
Sep-21-20 08:35AM  
Sep-15-20 07:00AM  
Sep-14-20 08:35AM  
08:03AM  
Sep-09-20 07:00AM  
Sep-02-20 07:00AM  
Sep-01-20 03:30PM  
Aug-13-20 05:15PM  
04:00PM  
Aug-11-20 07:00AM  
Aug-06-20 08:01AM  
Aug-05-20 12:30PM  
Jun-22-20 04:52PM  
08:00AM  
Jun-17-20 05:01PM  
Jun-15-20 07:00AM  
Jun-12-20 12:00PM  
10:43AM  
Jun-02-20 05:27AM  
May-20-20 08:03AM  
May-12-20 05:25PM  
04:05PM  
May-06-20 08:03AM  
May-05-20 08:03AM  
Apr-21-20 08:30AM  
Apr-13-20 12:45PM  
Mar-27-20 07:35AM  
Mar-26-20 05:15PM  
04:01PM  
03:00PM  
Mar-24-20 08:30AM  
Mar-19-20 04:05PM  
Mar-17-20 08:30AM  
Mar-10-20 08:30AM  
Mar-03-20 08:00AM  
Feb-27-20 08:00AM  
Feb-11-20 06:11PM  
Feb-06-20 09:00AM  
Feb-03-20 11:27AM  
Jan-08-20 10:07AM  
Jan-07-20 09:26AM  
09:19AM  
Jan-06-20 08:00AM  
Dec-12-19 08:00AM  
Dec-09-19 11:42AM  
Nov-14-19 04:01PM  
Nov-13-19 08:00AM  
aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead clinical product candidate is ATYR1923, a selective modulator of NRP2 for the treatment of patients with severe inflammatory lung diseases, including interstitial lung diseases (ILDs) and severe respiratory complications caused by COVID-19. Its product ATYR1923 is in Phase 1b/2a multi-center clinical trial for pulmonary sarcoidosis. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of various aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CLARKE JOHN KDirectorMay 21Sale4.342,50010,850108,083May 25 09:05 PM
SCHIMMEL PAULDirectorMay 18Buy3.9850,000199,000113,023May 20 08:55 AM
Shukla SanjayPresident and CEOMay 18Buy4.0110,00040,10018,298May 20 08:52 AM
Broadfoot Jill MarieChief Financial OfficerFeb 09Sale7.663902,9879,833Feb 09 09:15 PM
Shukla SanjayPresident and CEOFeb 09Sale7.667785,9598,298Feb 09 09:12 PM
CLARKE JOHN KDirectorSep 02Sale4.017,26029,113110,583Sep 03 09:47 PM
CLARKE JOHN KDirectorAug 28Sale4.00100400117,843Sep 03 09:47 PM
CLARKE JOHN KDirectorAug 27Sale4.095,44022,250117,943Aug 28 09:09 PM
CLARKE JOHN KDirectorAug 26Sale4.302,2009,451123,383Aug 28 09:09 PM
Broadfoot Jill MarieChief Financial OfficerJun 19Buy4.221,8507,8079,153Jun 23 04:27 PM
Shukla SanjayPresident and CEOJun 19Buy4.276,00025,6207,291Jun 23 04:23 PM